News
IMRN
0.8800
+5.87%
0.0488
Weekly Report: what happened at IMRN last week (1102-1106)?
Weekly Report · 1d ago
Emerging Growth Research Reports Continued Revenue Growth at Immuron
Barchart · 5d ago
Weekly Report: what happened at IMRN last week (1026-1030)?
Weekly Report · 11/02 10:03
Immuron Limited Announces Strategic Reset to Partner Clinical Assets and Reports FY26 Global Sales Revenue of $7.7m
NASDAQ · 10/28 17:41
Immuron Limited Announces Q1 Global Sales of AUD$2.2 million
NASDAQ · 10/27 15:11
Weekly Report: what happened at IMRN last week (1019-1023)?
Weekly Report · 10/26 10:03
Immuron Cuts U.S. ATM Offering Capacity to $2 Million in Updated F-3 Filing
TipRanks · 10/23 21:47
Weekly Report: what happened at IMRN last week (1012-1016)?
Weekly Report · 10/19 10:03
Immuron Calls November AGM to Decide Board Seats, Incentive Plan and Capital-Raising Capacity
TipRanks · 10/16 12:23
Immuron Reports Phase 2 Travelan Results Published In Scientific Reports; Stock Down
NASDAQ · 10/13 10:46
Immuron Announces Publication Of Data From Its Phase 2 Clinical Trial Of Once-Daily Oral Travelan In 'Scientific Reports'; Statistically Significant 50% Reduction In ETEC Challenge-Related Adverse Events Versus Placebo
Benzinga · 10/13 10:06
Weekly Report: what happened at IMRN last week (1005-1009)?
Weekly Report · 10/12 10:07
Weekly Report: what happened at IMRN last week (0928-1002)?
Weekly Report · 10/05 10:07
Weekly Report: what happened at IMRN last week (0921-0925)?
Weekly Report · 09/28 10:03
Weekly Report: what happened at IMRN last week (0914-0918)?
Weekly Report · 09/21 10:03
Weekly Report: what happened at IMRN last week (0907-0911)?
Weekly Report · 09/14 10:07
3 Penny Stocks to Watch Today, September 8
TipRanks · 09/08 14:49
Weekly Report: what happened at IMRN last week (0831-0904)?
Weekly Report · 09/07 10:02
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 09/04 17:06
Gold Falls Over 1%; American Outdoor Brands Shares Jump After Q1 Results
Benzinga · 09/04 16:13
More
Webull provides a variety of real-time IMRN stock news. You can receive the latest news about Immuron Ltd through multiple platforms. This information may help you make smarter investment decisions.
About IMRN
Immuron Limited is an Australia-based biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases. It operates through two segments: Research and development (R&D), and Hyperimmune products. The R&D segment is focused on R&D projects performed in Australia and the United States. Hyperimmune products segment is engaged in Travelan and Protectyn activities which occur predominantly in Australia, the United States and Canada. Its flagship products consist of Travelan and Protectyn. Travelan is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting traveler’s diarrhea and is sold in pharmacies throughout Australia. Protectyn is sold online and in health practitioner clinics and is marketed as an immune supplement to help maintain a healthy digestive function and liver. Its clinical programs include Travelan (IMM-124E), and IMM-529.